Deapartment of Laboratory Medicine, Thrombosis and Vascular Diseases Laboratory, School of Health & Biomedical Sciences-STEM College, RMIT University, Bundoora, Victoria, Australia
Research Article
Carfilzomib Potentiates Platelet Activation and Thrombus Growth
Author(s): Fehaid Alanazi, Isaac Goncalves, Kate L. Burbury, Faith A.A. Kwa, Gasim Dobie, Fahd A. Kuriri, Ezeldine K Abdalhabib and Denise E. Jackson*
Background: Multiple Myeloma (MM) patients treated with carfilzomib are at high risk of Venous
Thromboembolism (VTE), however, the underlying aetiology and mechanism remains unknown. Carfilzomib is an
irreversible Proteasome Inhibitor (PI) known to have cardiac toxicity, but less is known about its thrombogenic
effects. Platelets play a critical role in the pathogenesis of thrombosis; however, limited studies have reported the
effects of carfilzomib on platelet function.
Objectives: To characterise the effects of carfilzomib on platelet activation and thrombus formation.
Methods: Effects of carfilzomib on platelet activation, collagen adhesion and thrombus formation are characterised
using in-vitro and ex-vivo thrombosis models.
Results: Carfilzomib potentiated .. View more»